Ben Derman: Some thoughts on Elrantamab in light of approval.

Dr. Ben Derman, Assistant Professor at the University of Chicago, recently shared in a Twitter post:

“Some thoughts on Elrantamab in light of approval:
– Similar Overall Response Rate (ORR) to tec, but we have no data on Progression-Free Survival (PFS) or Duration of Response (DoR). I have yet to see a publication of MagnetisMM-3.
– Package insert: hospitalization recommends for the first 2 step-up doses but not the 3rd.
– q2wk for responders after cycle 6.”

Source: Ben Derman/Twitter